Australian biopharmaceutical company: Alternative Therapeutics Limited (ATHE)

Alternative Therapeutics Limited (NASDAQ: ATHE), formerly known as Prana Biotechnology Limited (formerly NASDAQ: PRAN), was founded in 1997 and changed to its current name in April 2019, Headquartered in Australia Melbourne, with 14 full-time employees, researches and develops therapeutic drugs for Alzheimer's disease, Huntington's disease, Parkinson's disease and other neurological diseases in Australia.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/athe.html

Alternative Therapeutics Limited (ATHE)

Alternative Therapeutics Limited focuses on the research and development of therapeutic drugs for Alzheimer's disease, Huntington's disease and other age-related degenerative diseases. Prana Biotechnology is developing first-rate treatments for neurodegenerative diseases in orphans. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/athe.html

The main candidate drugs of Alternative Therapeutics Limited include PBT434, the first of a new generation of small molecules, which aims to inhibit the aggregation of pathological proteins related to neurodegeneration. PBT434 has been shown to reduce the abnormal accumulation of α - synuclein and tau protein in disease animal models by restoring normal iron balance in the brain. In this way, it has great potential to treat various forms of atypical Parkinson's disease, such as multiple system atrophy (MSA) and progressive supranuclear paralysis (PSP). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/athe.html

PBT434 is in the phase I clinical trial of Parkinson's disease and other movement disorders; And PBT2, four Phase I studies and one Phase IIa clinical trial for patients with Alzheimer's disease have been completed. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/athe.html

Alternative Therapeutics Limited also completed the IMAGINE II biomarker imaging test of Alzheimer's disease; And the open label IMAGINE Extension study and Reach2HD Phase IIa trial of Huntington's disease. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/athe.html

Alternative Therapeutics Limited (ATHE) US equity investment

• reference material: